Alain Bouchard, MD
Cardiovascular Disease · Birmingham, ALNPI 1659336790
Payments from drug & device makers
Across 221 payments — averaging $8570.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$903K
- Janssen Research & Development, LLC$659K
- Endotronix, Inc.$181K
- Amgen$132K
- Abbott$9K
- Pfizer$7K
- plus $4K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 62 | $902,961 |
| Janssen Research & Development, LLC | 53 | $658,648 |
| Endotronix, Inc. | 3 | $180,624 |
| Amgen | 13 | $132,238 |
| Abbott | 7 | $8,907 |
| Pfizer | 20 | $6,785 |
| Boston Scientific | 9 | $2,760 |
| E.r. Squibb & Sons, L.L.C. | 11 | $229 |
| Edwards Lifesciences | 2 | $167 |
| Boehringer Ingelheim | 6 | $132 |
| Medtronic | 1 | $91 |
| Novo Nordisk | 3 | $70 |
| Amarin Pharma, Inc. | 4 | $59 |
| Sanofi-aventis U.S. LLC | 3 | $58 |
| Merck | 1 | $55 |
| Bayer | 3 | $51 |
| Johnson & Johnson | 3 | $46 |
| Scpharmaceuticals Inc. | 3 | $43 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $40 |
| Lantheus Medical Imaging, Inc. | 1 | $37 |
| AstraZeneca | 2 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Stryker | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Cardiovascular Systems Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| United Therapeutics Corporation | 1 | $5 |
How this compares
$1,894,189 in reported general payments places this provider in the 95th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Birmingham
- Mustafa AhmedBirmingham$2.5M
- Steven JonesBirmingham$1M
- Pankaj AroraBirmingham$889K
- Vikram AroraBirmingham$810K
- Robert BourgeBirmingham$590K
- Hutton BrantleyBirmingham$316K
- Thomas CawthonBirmingham$306K
- William RogersBirmingham$264K
- Farrell MendelsohnBirmingham$251K
- Jason ThompsonBirmingham$248K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.